2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Hemorrhage
13
Neoplasms
7
Leiomyoma
7
Breast Neoplasms
6
Postoperative Hemorrhage
4
Hematologic Neoplasms
4
Thrombocytopenia
3
Myofibroma
3
Meningioma
3
Blood Loss, Surgical
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Seroma
2
Seizures
2
Prostatic Neoplasms
2
Postoperative Complications
2
Ovarian Neoplasms
2
Menorrhagia
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Bone Neoplasms
2
Wrist Fractures
1
Urologic Diseases
1
Urinary Tract Infections
1
Urinary Retention
1
Thromboembolism
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Interventions
Cyclophosphamide
211
fludarabine phosphate
185
Azacitidine
160
fludarabine
144
Busulfan
140
Tacrolimus
120
Mycophenolic Acid
112
Cytarabine
111
Whole-Body Irradiation
107
Peripheral Blood Stem Cell Transplantation
99
Antilymphocyte Serum
97
Melphalan
91
Filgrastim
87
Cyclosporine
83
Decitabine
82
Methotrexate
79
venetoclax
63
Granulocyte Colony-Stimulating Factor
56
Radiotherapy
49
Stem Cell Transplantation
48
Thiotepa
47
Cord Blood Stem Cell Transplantation
43
Clofarabine
42
thymoglobulin
41
Specimen Handling
35
Etoposide
35
Methylprednisolone
34
Sirolimus
33
Biopsy
30
Injections
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Tranexamic Acid
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled